



For Further Information Contact:
Bioject Medical Technologies Inc.
Tony Chow
President and CEO
503-692-8001 ext. 4132

Management Change

Tigard, OR – February 12, 2015 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection therapy systems, announced that Mr. Tony Chow has been appointed President and CEO of the company. Mr. Tony Chow was previously Bioject’s CFO. His back ground includes being the Chief Financial Officer at American Laser Healthcare Corporation, a development stage medical device company with SEC reporting. Mr. Tony Chow brings professional services experience with over 30 years in financial management consulting, financial operations including SEC reporting, financial/IT/JSOX compliance, business development, client relationship management, and software product development/implementations. From 1997 to 1999, Mr. Tony Chow was the Director of Asia Sales and Marketing at Digital Video Systems, Inc. From 1994 to 1997, Mr. Tony Chow was the Chief Financial Officer and Corporate Controller at Craig Consumer Electronics, Inc. From 1989 to 1993, Mr. Tony Chow was the Controller of InterTherapy, Inc., a start-up company in the manufacturing and marketing on intravascular caterer ultrasound imaging system and catheter.

Mr. Tony Chow stated, “Since I joined Bioject, I have seen a great opportunity for Bioject to expand in the international markets, especially in Asia. I believe Bioject is heading in a direction of growth. I will focus on the operations of the business and work with Mark Logomasini, Director of Business Development, in the expansion our domestic and international markets.”

Mr. Mark Logomasini, the prior President and CEO, will assume the new role and title of Director of Business Development for Bioject, “It's been my pleasure to serve as Bioject's President the past few years. We've invested in new markets and created a path for growth going forward. The focus now is to realize a return on that investment that benefits all of our stakeholders. With much of our attention overseas and the need to be especially rigorous in the evaluation of new opportunities, it's appropriate that Mr. Tony Chow take the helm at this time.”

Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.

Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.

For more information about Bioject, visit www.bioject.com